Comments
According to a global analysis of advance market commitments (AMCs) for experimental vaccines, India has already pre-ordered 600 million doses by utilising its manufacturing capabilities and it is now aiming to secure another billion doses of the coronavirus vaccine.
This will help the country inoculate at least half its population, according to a report in the Hindustan Times .
India’s vaccine procurement comes second to the US, which has pre-ordered 810 million vaccine doses and is negotiating for another 1.6 billion doses.
Also read:
Related Stories
Covid-19 vaccine nationalism may cost global economy up to $1.2 trillion a year: Study
Countries pedalling ‘vaccine nationalism’ will likely hoard vaccines by striking a deal directly with pharma companies, the study saysAccording to some health experts, two doses of vaccine may be required to achieve immunity against the virus.
According to an analysis of purchasing agreements for Covid-19 vaccines carried by the US-based Duke Global Health Innovation Center, it will take around 4-5 years to produce enough vaccine to vaccinate the whole world.
However, countries have started vying for vaccines already. Some high-income countries and few middle-income countries with vaccine manufacturing capabilities have started pre-ordering vaccines even when the vaccines are still in their experimental stage. These countries have already secured around 3.8 billion doses of the vaccine.
After India, third comes the European Union that has so far secured 400 million doses and is now aiming for another 1.565 billion doses.
Also read:
Related Stories
Bharat Biotech to launch Covaxin in Q2 2021
The company has received approval from the DCGI to conduct Phase-3 clinical trial to establish the efficacy of the vaccine candidateLead author Andrea D Taylor, assistant director of programs at the Duke Global Health Innovation Center, said: “In terms of percent of the population covered by confirmed purchases, Canada has pre-purchased enough vaccine to cover 527 per cent of their population, followed by the UK at 277 per cent of their population.”
“Of course, it is important to remember that most likely only some of the vaccine purchases will come through, depending on regulatory approval,” said Taylor.
Also read:
Related Stories
Covid vaccine: Dr Reddy’s teams up with BIRAC for clinical trials of Sputnik V
Also read:
Also read:
Related Stories
Oxford Covid-19 vaccine triggers immune responses in elderly: Report
Since carlier studies had said old people were most vulnerable to coronavirus, health administration needs to be cautioned that positive immunogenicity tests don’t mean vaccine is safe, effective for old people, says report
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.